Oncology patient assistance programs
Novartis established the first global direct-to-patient access program – the Glivec International Patient Assistance Program (GIPAP) – to ensure patients with CML (chronic myeloid leukemia) or GIST (gastrointestinal stromal tumor), two rare cancers, receive treatment.
This program, one of the most far-reaching patient assistance programs ever implemented on a global scale, active in over 80 low to middle income countries, and donates to patients who are not insured, not reimbursed, cannot pay for the treatment privately and are in countries that have minimal reimbursement capabilities.1
The Max Foundation is our key collaborator in the administration of GIPAP globally. They provide patients with emotional support in addition to treatment.
In order to facilitate access to other products, Novartis has created the Novartis Oncology Access (NOA) program for products such as Tasigna (nilotinib)2 approved for use by CML patients, and Exjade3 a once-daily oral therapy for blood transfusion iron overload.
NOA provides sustainable access to Tasigna and Exjade where Novartis shares the cost of the treatment with patients through two types of cost-sharing models:
- Shared contribution, where local governments, charities or other payors share the cost of the medication with Novartis
- Co-pay, where Novartis and the patient share the cost of the medication on a sliding scale, depending upon the patient's ability to pay
Patients enrolled in NOA will be financially assessed on a yearly basis to determine their eligibility and level of contribution, if any.